ClinicalTrials.gg
Not yet recruitingNCT07147751Updated Nov 12, 2026

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

An observational study in Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL), sponsored by International Extranodal Lymphoma Study Group (IELSG). Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Observational

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy — 31 open to participants now, 51 under way, 12 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Italy.

Planned enrollment
14th of 22
100 · median 163
Started
2027
with 1 other
Observational
22 of 166
9 open now
Primary completion
2029-12
later than 47 of 50 live
Registered
156th of 166
by date

Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, this one is the 14th largest by planned enrollment of the 22 observational ones that give a count, is one of 2 that started in 2027, is one of 22 observational ones, reaches primary completion later than 47 of the 50 other live ones, and was the 156th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

31 of the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, or all of them as a file.
02

Study summary

PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.

Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.

Read the detailed description

Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' medical charts or electronic medical records upon receipt of ethical approval. Each patient enrolled in the study will be assigned a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data and to label biological samples. The coded biological material will be transferred at the Institute of Oncology Research in Bellinzona and the IRCCS Policlinico San Matteo Foundation in Pavia.

Diagnostic slides will be centrally revised by a panel of expert pathologists to confirm the diagnosis of PCNS-DLBCL. Health-related data will be collected in the e-CRFs. Data quality will be ensured by query generation.

Annotated baseline features will include: age, sex, the date of diagnosis, ECOG PS, IELSG index, clinical features (i.e. neurologic signs or symptoms, psychiatric and behavioural changes, systemic lymphoma symptoms, and comorbidities), imaging features (i.e. MRI report), disease involvements (i.e. bone marrow infiltrate, CSF, Vitro-retinal, basal ganglia, corpus callosum, brain stem, or cerebellum), laboratory features (i.e. complete blood count parameters, LDH levels, HIV infection evidence, HCV infection evidence, HBV infection evidence, EBV infection evidence, CMV infection evidence, and cerebrospinal fluid examination parameters).

Annotated follow-up features will include: the start date, the regimen, the response level and the date of response evaluation of the first-line therapy, the start date, the regimen, the response level and the date of response evaluation of the second-line therapy; the date of transplantation and the date of relapse.

Survival features will include date of death, cause of death, and date of last follow-up.

All FFPE samples will undergo a comprehensive histological review, including immunohistochemical investigations aimed to analyze the various cell populations and the microenvironment; EBER ISH assay to verify the presence of latent EBV-infection, FISH assays to verify the presence of translocations involving BCL2, BCL6, and MYC genes, and of CDKN2A and 6p21-22 (HLA locus) loss.

Molecular analyses on tumor samples will include: 1) DNA alteration analysis by means of NGS approach; 2) genome-wide methylation profiling (the sole epigenetic fingerprints that can be robustly assayed on FFPE material); 3) transcriptional profiling; 4) Ig heavy chain (IGH) rearrangements detection and immunoglobulin heavy-chain variable region gene (IGHV) analysis.

The results of all these analyses will be recorded in the clinical-biological database. Statistical analysis will be performed to integrate and correlate obtained biological data with collected radiomic and clinical information, to outline a precise PCNS-DLBCL multiomic profile and to investigate unraveled genes or cellular pathways, potentially useful for diagnostic, predictive, and therapeutic purposes. Hierarchical clustering analysis will be performed to identify genetic driver alterations and discover any subsets of tumors with distinctive multiomic (genetic/transcriptomic/radiomic) signatures.

03

Conditions studied

  • Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults patients with primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.
  2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.
  3. Availability of the baseline and follow-up annotations

Exclusion criteria

Exclusion Criteria:

  1. Established immunodeficiency conditions.
  2. Secondary CNS localizations of DLBCL
  3. Transformed DLBCL
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Prevalence of non-GC phenotype

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  2. Prevalence of mutations, copy number abnormalities, and structural variants

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  3. Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  4. Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  5. Prevalence of PCNS-DLBCL molecular subtypes defined by genetic methylation profile

    Time frame: 12 months: from the end of samples collection to the end of study analysis

Secondary outcomes

  1. Prevalence of molecular features of clinical, laboratory, and radiological features

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  2. Prevalence of PCNS-DLBCL immunological signatures defined by gene expression profiling

    Time frame: 12 months: from the end of samples collection to the end of study analysis

  3. 3. Prevalence of PCNS-DLBCL MicroRNA signatures defined by miRNOMA evaluation

    Time frame: 12 months: from the end of samples collection to the end of study analysis

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 29, 2025
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Sep 2026→Jan 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07147751
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

International Extranodal Lymphoma Study Group - IELSG
Contact
ielsg@ior.usi.ch
+41 58 666 7321
Marco Paulli, MD
study chair · Unit of Pathology, IRCCS Policlinico San Matteo Foundation and Department of Molecular Medicine, University of Pavia (IT)
Marco Lucioni, MD
study chair · Unit of Pathology, IRCCS Policlinico San Matteo Foundation and Department of Molecular Medicine, University of Pavia (IT)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion